Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
- PMID: 21859557
- PMCID: PMC3561586
- DOI: 10.1016/j.clcc.2011.03.001
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
Abstract
Conventional clinical and pathologic risk factors in stage II colon cancer provide limited prognostic information and do not predict response to adjuvant 5-fluorouracil-based chemotherapy. New prognostic and predictive biomarkers are needed to identify patients with highest recurrence risk who will receive the greatest absolute risk reduction from adjuvant chemotherapy. We review below the evidence for conventional risk factors in patients with node-negative colon cancer, followed by a discussion of promising new molecular and genetic markers in this malignancy. Gene expression profiling is an emerging tool with both prognostic and predictive potential in oncology. For patients with stage II colon cancer, the Oncotype DX Colon Cancer test is now commercially available as a prognostic marker, and the ColoPrint assay is expected to be released later this year. Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making.
Copyright © 2011. Published by Elsevier Inc.
Figures
Similar articles
-
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1. Ont Health Technol Assess Ser. 2010. PMID: 23074401 Free PMC article.
-
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413. JAMA Oncol. 2016. PMID: 26502222
-
Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.J Gastrointest Cancer. 2014 Dec;45(4):399-404. doi: 10.1007/s12029-014-9634-7. J Gastrointest Cancer. 2014. PMID: 24989938 Review.
-
Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.Oncologist. 2015 Feb;20(2):127-33. doi: 10.1634/theoncologist.2014-0325. Epub 2015 Jan 5. Oncologist. 2015. PMID: 25561511 Free PMC article.
-
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.World J Gastroenterol. 2018 Jul 21;24(27):2949-2973. doi: 10.3748/wjg.v24.i27.2949. World J Gastroenterol. 2018. PMID: 30038463 Free PMC article. Review.
Cited by
-
A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.Oncotarget. 2016 Apr 5;7(14):19060-71. doi: 10.18632/oncotarget.7956. Oncotarget. 2016. PMID: 26967049 Free PMC article.
-
Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II.Gastroenterol Res Pract. 2016;2016:2139489. doi: 10.1155/2016/2139489. Epub 2016 Jan 14. Gastroenterol Res Pract. 2016. PMID: 26884752 Free PMC article. Review.
-
A Predictive Genetic Signature for Response to Fluoropyrimidine-Based Neoadjuvant Chemoradiation in Clinical Stage II and III Rectal Cancer.Front Oncol. 2013 Nov 25;3:288. doi: 10.3389/fonc.2013.00288. eCollection 2013. Front Oncol. 2013. PMID: 24324931 Free PMC article.
-
Personalized medicine and the clinical laboratory.Einstein (Sao Paulo). 2014 Sep;12(3):366-73. doi: 10.1590/s1679-45082014rw2859. Einstein (Sao Paulo). 2014. PMID: 25295459 Free PMC article. Review.
-
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.J Clin Oncol. 2013 Dec 20;31(36):4512-9. doi: 10.1200/JCO.2012.47.3116. Epub 2013 Nov 12. J Clin Oncol. 2013. PMID: 24220557 Free PMC article.
References
-
- Horner MJRL, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute; 2009. FS2.
-
- Cancer in California . Department of Health Services; State of California: Dec, 2005. 1988-2002. 2005.[FS3]
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
-
- Quasar Collaborative G. Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9. [FS4][FS5] - PubMed
-
- Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical